1025799-39-6

Basic information

• Product Name: 2-(benzhydrylidene-amino)-3-cyclobutyl-propionic acid ethyl ester
• Synonyms: 2-(benzhydrylidene-amino)-3-cyclobutyl-propionic acid ethyl ester
• CAS NO: 1025799-39-6
• Molecular Weight: 335.446
• Mol File: 1025799-39-6.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 2-(benzhydrylidene-amino)-3-cyclobutyl-propionic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(benzhydrylidene-amino)-3-cyclobutyl-propionic acid ethyl ester(1025799-39-6)
• EPA Substance Registry System: 2-(benzhydrylidene-amino)-3-cyclobutyl-propionic acid ethyl ester(1025799-39-6)

Safety Data

• Hazardous Substances Data: 1025799-39-6(Hazardous Substances Data)

Usage

Class

Amino acid derivative

Modified form of

Phenylalanine

Uses

Development of peptide-based drugs and pharmaceuticals

Known for

Enhancing stability and activity of peptides

Importance in

Biotechnology and drug discovery

Ethyl ester group

Allows for easy modification and handling of the compound

Benzhydrylidene-amino group

Confers specific chemical and biological properties to the molecule

Cyclobutyl group

Confers specific chemical and biological properties to the molecule

Promise

Creation of peptide-based therapeutics targeting a wide range of diseases and medical conditions.

Upstream product

• 17247-58-4 (Bromomethyl)cyclobutane 
• 69555-14-2 ethyl N-diphenylmethylene glycine 

Downstream Products

• 565456-74-8 C₉H₁₇NO₂*ClH 
• 394735-25-2 {(S)-2-[(1R,2S,5S)-2-(2-Carbamoyl-1-cyclobutylmethyl-2-hydroxy-ethylcarbamoyl)-6,6-dimethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxo-ethyl}-carbamic acid tert-butyl ester 
• 394735-28-5 (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-(tert-butyl)ureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicylo[3.1.0]-hexane-2-carboxamide 
• 1036931-36-8 3-amino-4-cyclobutyl-2-hydroxybutanamide hydrochloride 
• 394735-22-9 tert-butyl 4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-ylcarbamate 
• 816430-02-1 ethyl 2-(tert-butoxycarbonylamino)-3-cyclobutylpropanoate 
• 394730-60-0 boceprevir 
• 394735-18-3 tert-butyl 3-cyclobutyl-1-(methoxy(methyl)amino)-1-oxopropan-2-ylcarbamate 
• 565456-75-9 2-(tert-butoxycarbonylamino)-3-cyclobutylpropanoic acid 
• 394735-20-7 (2-cyano-1-cyclobutylmethyl-2-hydroxyethyl)carbamic acid tert-butyl ester 
• 394735-19-4 (2-cyclobutyl-1-formylethyl)carbamic acid tert-butyl ester 
• 394735-17-2 ethyl 2-amino-3-cyclobutylpropanoate 

Relevant articles and documents

PROCESS FOR THE SYNTHESIS OF 3-AMINO-3-CYCLOBUTYLMETHYL-2-HYDROXYPROPIONAMIDE OR SALTS THEREOF

A process for preparing 3-amino-3-cyclobutylmethyl-2-hydroxypropionamide of the Formula I: [Chemical formula should be inserted here as it appears in the paper abstract.] or a salt thereof involves providing a compound of the Formula VI described herein in a solution comprising predominately dimethylsulfoxide (DMSO) and converting this compound directly to the compound of the Formula VIII described herein without working up or isolating the intermediate compound of the Formula VII described herein.

Methods for treating hepatitis C

Methods of treating hepatitis C are provided comprising using a therapeutically effective amount of at least one novel hepatitis C (“HCV”) protease inhibitor or, alternatively, at least one antiviral or immuno-modulating HCV agent, which is not an HCV protease inhibitor, for a first treatment period. Subsequently, a combination of the at least one novel hepatitis C (“HCV”) protease inhibitor and the at least one antiviral or immuno-modulating HCV agent are administered in a therapeutically effective amount for a second treatment period. The methods are provided for treating a wide variety of diseases, disorders and symptoms associated with hepatitis C virus by modulating the activity of HCV protease (for example HCV NS3/NS4a serine protease) in a subject.

ASYMMETRIC DOSING METHODS

A method of treating, preventing or ameliorating one or more symptoms of hepatitis C, or inhibiting cathepsin activity, in a subject is provided, in which at least one compound (e.g., a HCV protease inhibitor) is administered in one or more discrete dosages over a twenty-four hour time interval in an asymmetric pattern as to dosage amount and/or timing of dosage, wherein the at least one compound is selected from the group consisting of compounds of Formulae I-XXVI, described herein. Methods of modulating the activity of hepatitis C virus protease in a subject are also provided. Asymmetric dosing as to amount of dose and/or timing of dose permits adjustment of dosing to accommodate variations in drug metabolism and/or viral activity caused by viral cell division or a patient's circadian rhythms, thus delivering the maximum amount of dose at the time or times it is most effective.